Hospital-Treated Gram-Negative Infections | Unmet Need | Carbapenem Resistant Organisms | US/EU | 2018

Market Outlook

Carbapenem-resistant organisms (CROs) are responsible for difficult-to-treat, life-threatening gram-negative infections that require hospitalization. Of the currently marketed antibiotics, none were specifically developed for CROs. The recent launch of Merck & Co.’s Avycaz/Zaviceftaaddresses some of the unmet need in this area, but the majority of current treatments are combinations of generically available antibiotics, which have significant sideeffects and may extend the length of hospital stay. Thus, a high unmet need exists for the treatment of infections caused by CROs, witha significant commercial opportunity for novel agents.

Questions Answered

• What clinical and nonclinical factors are the key influencers in ID specialists’ prescribing decisions for the treatment of infections due to CROs? How do these different factors compare in terms of importance?
• How do current therapies used in the treatment of CROs—including Avycaz/Zavicefta or tigecycline—perform on clinical and nonclinical attributes?
• What are the key areas of unmet need that represent opportunities for developers of therapies in the treatment of CROs? How do these needs differ between European and U.S. ID specialists?
• What trade-offs across different clinical and nonclinical attributes and price are acceptable to U.S. and European ID specialists for a hypothetical new agent for the treatment of CROs?

Product Description

Unmet Need: Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, and Germany.

Primary research: Survey of 62 U.S. and 35 European ID specialists fielded in March 2018.

Key companies: Achaogen, Allergan, Merck & Co., Melinta Therapeutics, Pfizer, Polyphor, Shionogi, and Tetraphase.

Key drugs: Avycaz/Zavicefta, cefiderocol, eravacycline, imipenem/cilastatin, colistin, imipenem/cilastatin/relebactam, meropenem, murepavadin, tigecycline, and Vabomere.